Avience Biomedicals SME IPO Subscription Status
The Avience Biomedicals SME IPO opens on 18 June 2026. Subscription data will be updated here once bidding starts.
Allotment will be finalised on 23 June 2026. The stock is scheduled to list on NSE and BSE on 25 June 2026.
Issue Price
Rs 208.00
GMP Today
Rs 70.00 (+33.65%)
Overall Subscription
-
Issue Size
₹30.24 Cr
Allotment Date
23 Jun 2026
Listing Date
25 Jun 2026
Avience Biomedicals SME IPO Allotment Chances
Based on the final subscription data, here is a realistic view of allotment probability by category.
QIB Category: QIB allotment is discretionary and handled by the book running lead managers. Retail investors do not participate in this category.
Check the Avience Biomedicals SME IPO Allotment Status page from 23 June 2026 for your allotment result.
Avience Biomedicals SME IPO GMP After Subscription
GMP for Avience Biomedicals SME stands at Rs 70.00 today, giving an estimated listing price of Rs 278.00 per share.
Track live GMP on the Avience Biomedicals SME IPO GMP Today page or the IPOwiz Live IPO GMP Tracker.
Avience Biomedicals SME IPO Key Dates
| Event | Date |
|---|---|
| IPO Open Date | 18 June 2026 |
| IPO Close Date | 22 June 2026 |
| Allotment Date | 23 June 2026 |
| Refund Initiation | 24 June 2026 |
| Share Credit to Demat | 24 June 2026 |
| Listing Date | 25 June 2026 |
| Minimum Investment | Rs 2,49,600.00 |
| Lot Size | 600 shares |
About Avience Biomedicals SME
Avience Biomedicals Limited, incorporated in June 2024, is an ISO-certified healthcare and biotechnology solutions company. The enterprise specializes in manufacturing, supplying, and exporting high-precision molecular diagnostic formulations, in-vitro diagnostics (IVD) rapid test kits, serology products, and automated biochemistry and hematology analyzers. Operating entirely on business-to-business (B2B) and business-to-government (B2G) frameworks, Avience provides cost-effective diagnostics to premier hospital networks, pathology labs, and research institutions.
Understanding Subscription Categories
QIB - Qualified Institutional Buyers
Includes foreign institutional investors, domestic financial institutions, mutual funds, and other qualified institutions. QIB demand is considered the most reliable indicator of institutional confidence in an IPO.
NII - Non-Institutional Investors
High net worth individuals applying above Rs 2 lakh. Divided into bNII (above Rs 10 lakh) and sNII (Rs 2 lakh to Rs 10 lakh). NII allotment is proportional.
IND - Individual Investors
Investors applying up to Rs 2 lakh per PAN. Allotment is by lottery when oversubscribed. Minimum one lot per successful applicant.
Avience Biomedicals SME IPO GMP Today
Live GMP, listing price estimate, and listing gain
Avience Biomedicals SME IPO Allotment Status
Check allotment result on allotment date
Avience Biomedicals SME IPO Details
Financials, peers, strengths, and review
All IPO Subscription Status
Subscription for all active IPOs
Avience Biomedicals SME IPO Subscription FAQs
What is the current subscription status of Avience Biomedicals SME?
Avience Biomedicals SME IPO overall subscription is - based on shares applied. QIB is at N/A, NII at N/A, and retail at N/A. Data is updated during the subscription window from 18 June 2026 to 22 June 2026.
What are the allotment chances for retail investors?
Retail allotment chances depend on final oversubscription. Allotment is by lottery when retail subscription exceeds 1x.
When will Avience Biomedicals SME allotment be finalised?
Allotment will be finalised on 23 June 2026. You can check your allotment status on the Avience Biomedicals SME IPO Allotment Status page from that date.
What happens after subscription closes?
After the subscription closes, the registrar processes all applications and finalises allotment on 23 June 2026. Refunds for unsuccessful applications are typically initiated before listing. Shares are credited to demat accounts before the listing date on 25 June 2026.
Can I apply after subscription closes?
No. Applications must be submitted before the subscription closes on 22 June 2026. Late applications are rejected automatically.
What is the difference between QIB, NII, and IND subscription?
QIB includes institutional investors such as mutual funds, FIIs, and banks. NII includes high net worth individuals applying above Rs 2 lakh. IND includes individual investors applying up to Rs 2 lakh. Each category has separate reservation and different allotment rules.
How does subscription affect allotment chances?
Higher oversubscription means fewer applicants receive allotment. In the retail category, allotment is by lottery. In the NII category, allotment is proportional. At - overall subscription, competition for shares is moderate.
What is the issue size and lot size for Avience Biomedicals SME?
Issue size is ₹30.24 Cr. Lot size is 600 shares. Minimum investment at the issue price of Rs 208.00 is Rs 2,49,600.00 per lot (minimum 2 lots for SME).
For allotment results from 23 June 2026, visit the Avience Biomedicals SME IPO Allotment Status page. For listing day updates on 25 June 2026, download the IPOwiz App.
Reviewed by Dinesh Agrawal
15+ years in Indian capital markets and IPO research. Subscription data verified before publish.